116 related articles for article (PubMed ID: 27338556)
21. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
22. Antibody-dependent cellular cytotoxicity and cytokine/chemokine secretion by KHYG-1 cells stably expressing FcγRIIIA.
Kobayashi E; Motoi S; Sugiura M; Kajikawa M; Kojima S; Kohroki J; Masuho Y
Immunol Lett; 2014 Sep; 161(1):59-64. PubMed ID: 24841426
[TBL] [Abstract][Full Text] [Related]
23. Effects of FCGRIIIa-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab.
Kimura K; Kobayashi D; Hatoyama S; Yamamoto M; Takayanagi R; Yamada Y
APMIS; 2017 Dec; 125(12):1102-1107. PubMed ID: 28913867
[TBL] [Abstract][Full Text] [Related]
24. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
25. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
[TBL] [Abstract][Full Text] [Related]
26. Functional and clinical consequences of changes to natural killer cell phenotypes driven by chronic cytomegalovirus infections.
Lee S; Doualeh M; Affandi JS; Makwana N; Irish A; Price P
J Med Virol; 2019 Jun; 91(6):1120-1127. PubMed ID: 30636352
[TBL] [Abstract][Full Text] [Related]
27. NK Cells Expressing the Inhibitory Killer Immunoglobulin-Like Receptors (iKIR) KIR2DL1, KIR2DL3 and KIR3DL1 Are Less Likely to Be CD16+ than Their iKIR Negative Counterparts.
Isitman G; Tremblay-McLean A; Lisovsky I; Bruneau J; Lebouché B; Routy JP; Bernard NF
PLoS One; 2016; 11(10):e0164517. PubMed ID: 27732638
[TBL] [Abstract][Full Text] [Related]
28. High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19.
Vietzen H; Danklmaier V; Zoufaly A; Puchhammer-Stöckl E
Genet Med; 2022 Jul; 24(7):1449-1458. PubMed ID: 35488894
[TBL] [Abstract][Full Text] [Related]
29. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells.
Peruzzi G; Femnou L; Gil-Krzewska A; Borrego F; Weck J; Krzewski K; Coligan JE
J Immunol; 2013 Aug; 191(4):1883-94. PubMed ID: 23851692
[TBL] [Abstract][Full Text] [Related]
30. The FCGR3A 158 V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection.
Litjens N; Peeters A; Gestel JK; Klepper M; Betjes M
Sci Rep; 2021 Apr; 11(1):7903. PubMed ID: 33846428
[TBL] [Abstract][Full Text] [Related]
31. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.
Tang CC; Isitman G; Bruneau J; Tremblay C; Bernard NF; Kent SJ; Parsons MS
Clin Exp Immunol; 2015 Aug; 181(2):275-85. PubMed ID: 25644502
[TBL] [Abstract][Full Text] [Related]
32. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.
Grier JT; Forbes LR; Monaco-Shawver L; Oshinsky J; Atkinson TP; Moody C; Pandey R; Campbell KS; Orange JS
J Clin Invest; 2012 Oct; 122(10):3769-80. PubMed ID: 23006327
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.
Böttcher S; Ritgen M; Brüggemann M; Raff T; Lüschen S; Humpe A; Kneba M; Pott C
J Immunol Methods; 2005 Nov; 306(1-2):128-36. PubMed ID: 16181633
[TBL] [Abstract][Full Text] [Related]
34. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.
Mishima Y; Terui Y; Mishima Y; Kuniyoshi R; Matsusaka S; Mikuniya M; Kojima K; Hatake K
Int Immunol; 2012 Aug; 24(8):477-83. PubMed ID: 22438420
[TBL] [Abstract][Full Text] [Related]
35. [Effect of FCGR3A Polymorphisms on Antibody-dependent Cetuximab-mediated Cytotoxicity in A549 Cells].
Li JY; Zhu YY; Zhang GQ; Sun SJ; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Dec; 37(6):645-9. PubMed ID: 26725386
[TBL] [Abstract][Full Text] [Related]
36. Enrichment of Genetic Variants for Rheumatoid Arthritis within T-Cell and NK-Cell Enhancer Regions.
Freudenberg J; Gregersen P; Li W
Mol Med; 2015 Mar; 21(1):180-4. PubMed ID: 25794145
[TBL] [Abstract][Full Text] [Related]
37. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
[TBL] [Abstract][Full Text] [Related]
38. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
39. Pyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques.
Matlawska-Wasowska K; Gale JM; Nickl CK; Khalili P; Shirley B; Wilson BS; Vasef MA; Winter SS
Mol Diagn Ther; 2014 Dec; 18(6):665-73. PubMed ID: 25230857
[TBL] [Abstract][Full Text] [Related]
40. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
